Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turkey Slashes Prices Yet Again, Pharmas Prepare For Worst Case Scenario

This article was originally published in PharmAsia News

Executive Summary

A third round of price cuts and substantial currency depreciation has manufacturers questioning investment in Turkey.

You may also be interested in...



GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..

Turkey Again Slashes Drug Prices; Manufacturers And Pharmacists Cry Foul

The Turkish Social Security Institution or SGK hiked institutional pharmaceutical discounts with a new regulation in December 2010, imposing an additional 9.5% price cut to its reference pricing system

China Hits Two Billion COVID Jabs But More Effective mRNA Shots Elude

Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.

Topics

Related Companies

UsernamePublicRestriction

Register

SC076733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel